Updated: Nov 27, 2023 Author: Elwyn C Cabebe, MD; Chief Editor: N Joseph Espat, MD, MS, FACS more...60 FeedbackColorectal Cancer Screening Guidelines on colorectal screening have been issued by the following organizations: American Cancer Society (ACS), US Multi-Society Task Force on ...
From genomic profiling to targeted therapy, treatment for colorectal cancer has become more personalised over the last decade. Dr Zee Ying Kiat, Senior Consultant, Medical Oncology explains more. Singapore has one of the highest numbers of colorectal cancer in Asia, along with ...
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China(English version) diagnosiscoloncancer2.Diagnosis 2.1 Clinical manifestations 2.2 Disease history and family history 2.3 Physical examination 2.4 Clinical laboratory examinations 2.5 Endoscopy 2.6 Imaging 2.6.1 Common testing ...
In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50 years has increased, which is referred to as early-onset CRC or young-onset CRC (YO-CRC). YO-CRC is expected to account for 11% of colon cancers and 23% of rectal
Colorectal cancer (CRC) is the third most common cancer worldwide [1]. In most cases, CRC develops from a premalignant polypoid colorectal lesion [2]. Endoscopic detection and subsequent removal of these polyps prevent CRC-related death [3]. The vast majority can be removed endoscopically during...
The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news ...
This systematic review to support the 2021 US Preventive Services Task Force Recommendation Statement on screening for colorectal cancer summarizes
Histopathologic assessment is indispensable for diagnosing colorectal cancer (CRC). However, manual evaluation of the diseased tissues under the microscope cannot reliably inform patient prognosis or genomic variations crucial for treatment selections. T
both of which are FDA approved in HER-positive breast cancer treatment, helped patients with HER2-amplified metastatic CRC to gain an overall response rate of 32%, a PFS of 2.9 months and an OS of 11.5 months, which may be even better in patients with RAS-wild-type CRCs (PFS: 5.3 mont...
Colorectal cancer (CRC) is among the commonest malignant tumors of humans. Existing evidence has linked the poor prognosis of CRC with high expression of stromal antigen 3 (STAG3), but, the exact biological effect of STAG3 in CRC is still unclear. The aim of this research is to reveal th...